Linked e-resources
Details
Table of Contents
Intro; Contents; Abbreviations; Part I: Precision Medicine; 1: Precision Medicine in the Intensive Care Unit: Identifying Opportunities and Overcoming Barriers; 1.1 Introduction; 1.2 Definitions; 1.3 Diagnosis; 1.4 Treatment; 1.5 Potential Conflicts/Weaknesses; 1.6 Pharmacokinetics; 1.7 Data Collection and Analysis; 1.8 The Future; 1.9 Conclusion; References; 2: Precision Delivery in Critical Care: Balancing Prediction and Personalization; 2.1 Introduction; 2.2 A Changing Landscape: The Fourth Industrial Revolution; 2.3 Precision Delivery in Healthcare
2.4 Critical Care: A Risk-Based Specialty2.5 Novel Capabilities with Improved Data and Computation; 2.6 Current Risk Prediction Applications in Critical Care; 2.7 Heterogeneity: The Hallmark of Severe and Critical Illness; 2.8 Unsupervised Machine Learning Approaches and Personalization; 2.9 Considerations: Assessing the Value of Increasing Model Performance; 2.10 Considerations: Moving Beyond Clinical Data; 2.11 Considerations: Risk Prediction Model Fatigue; 2.12 Considerations: Workforce Development and Artificial Intelligence; 2.13 Conclusion; References
Part II: Acute Respiratory Failure and ARDS3: Acute Respiratory Failure in the Oncologic Patient: New Era, New Issues; 3.1 Introduction; 3.2 The Evolution of Oncologic Critical Care over Time; 3.3 Differences Between Oncologic and Non-oncologic Patients; 3.4 Causes of Acute Respiratory Failure in Oncologic Patients; 3.4.1 Infectious; 3.4.2 Non-infectious: Disease-Related; 3.4.3 Non-infectious: Treatment-Related; 3.4.3.1 Non-infectious: Treatment-Related-Novel Treatments; 3.4.3.2 Non-infectious: Treatment-Related-Tumor Lysis Syndrome
3.4.3.3 Non-infectious: Treatment-Related-Radiation3.4.3.4 Non-infectious: Treatment-Related-Immune Reconstitution; 3.5 Diagnostic Work-Up and Undiagnosed Acute Respiratory Failure; 3.6 Management; 3.6.1 Supportive Care During Early Acute Hypoxemic Respiratory Failure; 3.6.2 Supportive Care During ARDS; 3.7 Prognosis and Future Research Considerations; 3.8 Conclusion; References; 4: Universal Low Tidal Volume: Early Initiation of Low Tidal Volume Ventilation in Patients with and without ARDS; 4.1 Introduction; 4.2 Timing of Low Tidal Ventilation in ARDS and in Non-ARDS
4.3 Review and Update of Evidence in the Operating Room4.4 Acute Respiratory Failure in the Emergency Department; 4.5 Therapeutic Momentum: From the ED to the ICU; 4.6 Lung Protective Ventilation After Cardiac Arrest; 4.7 Lung Protective Ventilation in Patients with Increased Intracranial Pressure or Traumatic Brain Injury; 4.8 Perceived Barriers to Low Tidal Volume Ventilation in ARDS and Non-ARDS; 4.9 Under-Recognition of ARDS and Reluctance to Use Low Tidal Volume Ventilation in At-Risk Patients with Acute Respiratory Failure; 4.10 Calculation of Predicted Body Weight
2.4 Critical Care: A Risk-Based Specialty2.5 Novel Capabilities with Improved Data and Computation; 2.6 Current Risk Prediction Applications in Critical Care; 2.7 Heterogeneity: The Hallmark of Severe and Critical Illness; 2.8 Unsupervised Machine Learning Approaches and Personalization; 2.9 Considerations: Assessing the Value of Increasing Model Performance; 2.10 Considerations: Moving Beyond Clinical Data; 2.11 Considerations: Risk Prediction Model Fatigue; 2.12 Considerations: Workforce Development and Artificial Intelligence; 2.13 Conclusion; References
Part II: Acute Respiratory Failure and ARDS3: Acute Respiratory Failure in the Oncologic Patient: New Era, New Issues; 3.1 Introduction; 3.2 The Evolution of Oncologic Critical Care over Time; 3.3 Differences Between Oncologic and Non-oncologic Patients; 3.4 Causes of Acute Respiratory Failure in Oncologic Patients; 3.4.1 Infectious; 3.4.2 Non-infectious: Disease-Related; 3.4.3 Non-infectious: Treatment-Related; 3.4.3.1 Non-infectious: Treatment-Related-Novel Treatments; 3.4.3.2 Non-infectious: Treatment-Related-Tumor Lysis Syndrome
3.4.3.3 Non-infectious: Treatment-Related-Radiation3.4.3.4 Non-infectious: Treatment-Related-Immune Reconstitution; 3.5 Diagnostic Work-Up and Undiagnosed Acute Respiratory Failure; 3.6 Management; 3.6.1 Supportive Care During Early Acute Hypoxemic Respiratory Failure; 3.6.2 Supportive Care During ARDS; 3.7 Prognosis and Future Research Considerations; 3.8 Conclusion; References; 4: Universal Low Tidal Volume: Early Initiation of Low Tidal Volume Ventilation in Patients with and without ARDS; 4.1 Introduction; 4.2 Timing of Low Tidal Ventilation in ARDS and in Non-ARDS
4.3 Review and Update of Evidence in the Operating Room4.4 Acute Respiratory Failure in the Emergency Department; 4.5 Therapeutic Momentum: From the ED to the ICU; 4.6 Lung Protective Ventilation After Cardiac Arrest; 4.7 Lung Protective Ventilation in Patients with Increased Intracranial Pressure or Traumatic Brain Injury; 4.8 Perceived Barriers to Low Tidal Volume Ventilation in ARDS and Non-ARDS; 4.9 Under-Recognition of ARDS and Reluctance to Use Low Tidal Volume Ventilation in At-Risk Patients with Acute Respiratory Failure; 4.10 Calculation of Predicted Body Weight